OmniSeq Secures New York State Approval for Cancer Panel; Partners With Cure Forward | GenomeWeb

NEW YORK (GenomeWeb) – Roswell Park Cancer Institute subsidiary OmniSeq said today that it has received New York State Laboratory Evaluation Program approval for a 144-gene next-generation sequencing pan-cancer panel.

The OmniSeq Comprehensive Panel is designed to molecularly profile tumors in order to guide treatment decisions. It provides information on genes linked to more than 650 therapies and 850 clinical trials and can identify drugs that would not be appropriate for certain patients due to their genomic profile, according to the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.

Dec
13
Sponsored by
Agilent Technologies

This webinar will discuss a genomic strategy that detects single nucleotide variants and copy number variants in a single assay.

Dec
15
Sponsored by
PierianDx

This webinar will be an interactive roundtable discussion on established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting.